Unique 20q deletion associated with primary amyloidosis and multiple myeloma

Regina L. Chorsky, K. L. Satya-Prakash, Jonathan S. Krauss, Abdullah Kutlar, Linda K. Hendricks

Research output: Contribution to journalArticle

Abstract

We report here a unique case of 46,XY,del(20)(ql 1.2)[6]/46,XY[6] in a 76 year old man with primary amyloidosis (AL) and multiple myeloma. The patient was investigated for fatigue, hepatomegaly, and nephrotic syndrome and died several weeks later. He had 2.1 g/dl circulating IgG-lambda with IgG-lambda and free lambda light chains in the urine. The bone marrow was extensively replaced by vacuolated plasma (Mott) cells and also had dysplastic, megaloblastoid features. Amyloid and amyloid-like material were identified in both bone marrow and recto-sigmoid biopsies. The 20q deletion has been associated with myelodysplastic syndromes and acute myelogenous leukemia, however, this cytogenetic abnormality has not been reported with either amyloidosis or multiple myeloma. Recently, however, 2 myeloma patients were identifed with a t(9;20)(p24;qll.2) (Cancer Genet Cytogenet 1996;90:106-8), suggesting that aberrations of the q 11.2 region of chromosome 20 might be associated with myeloma. Also, a case of myeloma and myelodysplasia originating in a common clone has been reported (Cancer Genet Cytogenet 1998; 100:31 -5), however, although our patient had evidence of myelodysplasia the cytogenetic abnormalities identified here differ from those discovered in the other patient. If our patient's short clinical course is considered, this cytogenetic finding might define a subset of myeloma patients with more aggressive disease. Cytogenetic and morphologic studies are presented and the literature is reviewed regarding the relationship of cytogenetic findings to prognosis.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART II
StatePublished - Dec 1 2000

Fingerprint

Multiple Myeloma
Amyloid
Bone
Immunoglobulin G
Biopsy
Chromosomes
Aberrations
Cytogenetics
Viverridae
Fatigue of materials
Plasmas
Chromosome Aberrations
Bone Marrow
Chromosomes, Human, Pair 20
Hepatomegaly
Myelodysplastic Syndromes
Nephrotic Syndrome
Sigmoid Colon
Amyloidosis
Plasma Cells

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chorsky, R. L., Satya-Prakash, K. L., Krauss, J. S., Kutlar, A., & Hendricks, L. K. (2000). Unique 20q deletion associated with primary amyloidosis and multiple myeloma. Blood, 96(11 PART II).

Unique 20q deletion associated with primary amyloidosis and multiple myeloma. / Chorsky, Regina L.; Satya-Prakash, K. L.; Krauss, Jonathan S.; Kutlar, Abdullah; Hendricks, Linda K.

In: Blood, Vol. 96, No. 11 PART II, 01.12.2000.

Research output: Contribution to journalArticle

Chorsky, RL, Satya-Prakash, KL, Krauss, JS, Kutlar, A & Hendricks, LK 2000, 'Unique 20q deletion associated with primary amyloidosis and multiple myeloma', Blood, vol. 96, no. 11 PART II.
Chorsky RL, Satya-Prakash KL, Krauss JS, Kutlar A, Hendricks LK. Unique 20q deletion associated with primary amyloidosis and multiple myeloma. Blood. 2000 Dec 1;96(11 PART II).
Chorsky, Regina L. ; Satya-Prakash, K. L. ; Krauss, Jonathan S. ; Kutlar, Abdullah ; Hendricks, Linda K. / Unique 20q deletion associated with primary amyloidosis and multiple myeloma. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{dab209309acf4b40839fae6681372ade,
title = "Unique 20q deletion associated with primary amyloidosis and multiple myeloma",
abstract = "We report here a unique case of 46,XY,del(20)(ql 1.2)[6]/46,XY[6] in a 76 year old man with primary amyloidosis (AL) and multiple myeloma. The patient was investigated for fatigue, hepatomegaly, and nephrotic syndrome and died several weeks later. He had 2.1 g/dl circulating IgG-lambda with IgG-lambda and free lambda light chains in the urine. The bone marrow was extensively replaced by vacuolated plasma (Mott) cells and also had dysplastic, megaloblastoid features. Amyloid and amyloid-like material were identified in both bone marrow and recto-sigmoid biopsies. The 20q deletion has been associated with myelodysplastic syndromes and acute myelogenous leukemia, however, this cytogenetic abnormality has not been reported with either amyloidosis or multiple myeloma. Recently, however, 2 myeloma patients were identifed with a t(9;20)(p24;qll.2) (Cancer Genet Cytogenet 1996;90:106-8), suggesting that aberrations of the q 11.2 region of chromosome 20 might be associated with myeloma. Also, a case of myeloma and myelodysplasia originating in a common clone has been reported (Cancer Genet Cytogenet 1998; 100:31 -5), however, although our patient had evidence of myelodysplasia the cytogenetic abnormalities identified here differ from those discovered in the other patient. If our patient's short clinical course is considered, this cytogenetic finding might define a subset of myeloma patients with more aggressive disease. Cytogenetic and morphologic studies are presented and the literature is reviewed regarding the relationship of cytogenetic findings to prognosis.",
author = "Chorsky, {Regina L.} and Satya-Prakash, {K. L.} and Krauss, {Jonathan S.} and Abdullah Kutlar and Hendricks, {Linda K.}",
year = "2000",
month = "12",
day = "1",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Unique 20q deletion associated with primary amyloidosis and multiple myeloma

AU - Chorsky, Regina L.

AU - Satya-Prakash, K. L.

AU - Krauss, Jonathan S.

AU - Kutlar, Abdullah

AU - Hendricks, Linda K.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - We report here a unique case of 46,XY,del(20)(ql 1.2)[6]/46,XY[6] in a 76 year old man with primary amyloidosis (AL) and multiple myeloma. The patient was investigated for fatigue, hepatomegaly, and nephrotic syndrome and died several weeks later. He had 2.1 g/dl circulating IgG-lambda with IgG-lambda and free lambda light chains in the urine. The bone marrow was extensively replaced by vacuolated plasma (Mott) cells and also had dysplastic, megaloblastoid features. Amyloid and amyloid-like material were identified in both bone marrow and recto-sigmoid biopsies. The 20q deletion has been associated with myelodysplastic syndromes and acute myelogenous leukemia, however, this cytogenetic abnormality has not been reported with either amyloidosis or multiple myeloma. Recently, however, 2 myeloma patients were identifed with a t(9;20)(p24;qll.2) (Cancer Genet Cytogenet 1996;90:106-8), suggesting that aberrations of the q 11.2 region of chromosome 20 might be associated with myeloma. Also, a case of myeloma and myelodysplasia originating in a common clone has been reported (Cancer Genet Cytogenet 1998; 100:31 -5), however, although our patient had evidence of myelodysplasia the cytogenetic abnormalities identified here differ from those discovered in the other patient. If our patient's short clinical course is considered, this cytogenetic finding might define a subset of myeloma patients with more aggressive disease. Cytogenetic and morphologic studies are presented and the literature is reviewed regarding the relationship of cytogenetic findings to prognosis.

AB - We report here a unique case of 46,XY,del(20)(ql 1.2)[6]/46,XY[6] in a 76 year old man with primary amyloidosis (AL) and multiple myeloma. The patient was investigated for fatigue, hepatomegaly, and nephrotic syndrome and died several weeks later. He had 2.1 g/dl circulating IgG-lambda with IgG-lambda and free lambda light chains in the urine. The bone marrow was extensively replaced by vacuolated plasma (Mott) cells and also had dysplastic, megaloblastoid features. Amyloid and amyloid-like material were identified in both bone marrow and recto-sigmoid biopsies. The 20q deletion has been associated with myelodysplastic syndromes and acute myelogenous leukemia, however, this cytogenetic abnormality has not been reported with either amyloidosis or multiple myeloma. Recently, however, 2 myeloma patients were identifed with a t(9;20)(p24;qll.2) (Cancer Genet Cytogenet 1996;90:106-8), suggesting that aberrations of the q 11.2 region of chromosome 20 might be associated with myeloma. Also, a case of myeloma and myelodysplasia originating in a common clone has been reported (Cancer Genet Cytogenet 1998; 100:31 -5), however, although our patient had evidence of myelodysplasia the cytogenetic abnormalities identified here differ from those discovered in the other patient. If our patient's short clinical course is considered, this cytogenetic finding might define a subset of myeloma patients with more aggressive disease. Cytogenetic and morphologic studies are presented and the literature is reviewed regarding the relationship of cytogenetic findings to prognosis.

UR - http://www.scopus.com/inward/record.url?scp=33748540372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748540372&partnerID=8YFLogxK

M3 - Article

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -